Filing Details
- Accession Number:
- 0001562180-23-002039
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-03-01 16:06:17
- Reporting Period:
- 2023-02-27
- Accepted Time:
- 2023-03-01 16:06:17
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1517022 | Akebia Therapeutics Inc. | AKBA | Pharmaceutical Preparations (2834) | 208756903 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1669737 | Michel Dahan | C/O Akebia Therapeutics, Inc. 245 First Street Cambridge MA 02142 | Svp, Chief Operating Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-02-27 | 10,090 | $0.81 | 289,927 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
- Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.
Billionaire Hedge Funds
